Therapeutic efficiency of IL-2 gene transduced tumor vaccine for head and neck carcinoma

Cancer Letters

Volumn 152, Issue 2, 2000, Pages 175-185

  Mizuno, Hiromi ^a   Yanoma, Shunsuke ^b   Nishimura, Goshi ^a   Hattori, Satoshi ^a   Ito, Takaaki ^a   Okudera, Kohji ^a   Tsukuda, Mamoru ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

Author keywords

Gene therapy; Head and neck carcinoma; Herpes simplex virus type 1; IL 2 gene

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; TUMOR VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL STRAIN KB; CONTROLLED STUDY; CYTOTOXICITY; GENETIC TRANSDUCTION; HEAD AND NECK CARCINOMA; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; IN VITRO STUDY; IRRADIATION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL;

ANIMALS; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; CERCOPITHECUS AETHIOPS; FEMALE; GENE THERAPY; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PLASMIDS; SIMPLEXVIRUS; SPLEEN; TIME FACTORS; TUMOR CELLS, CULTURED; VERO CELLS;

HERPES; HUMAN HERPESVIRUS 1; MUS MUSCULUS;

EID: 0034194841     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00336-0     Document Type: Article

References (32)

1. Gillis S., Smith K.A. Long term culture of tumor-specific cytotoxic T cells. Nature. 268:1977;154-156.
2. Cheever M.A., Greenberg P.D., Fefer A., Gillis S. Augmentation of anti-tumor therapeutic efficacy of long term cultured T lymphocytes by in vivo administration of purified interleukin 2. J. Exp. Med. 155:1982;968-980.
3. Kuribayashi K., Gillis S., Kern D.E., Henney C.S. Murine NK cell cultures: effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity. J. Immunol. 126:1981;2321-2327.
4. Henney C.S., Kern D.E., Gillis S. Cytotoxic responses: the regulatory influence of interleukin-2. Transplant. Proc. 14:1982;565-569.
5. Rosenberg S.A., Lotze M.T., Muul L.M., Chang A.E., Avis F.P., Leitman S., Lineban W.M., Robertson C.N., Lee R.E., Rubin J.T., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin alone. N. Engl. J. Med. 316:1987;889-897.
6. West W.H., Tauer K.W., Yannelli J.R., Marshall G.D., Orr D.W., Thyrman G.B., Oldham R.K. Constant-infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. 316:1987;898-905.
7. Yeung R.S., Vollmer C., Taylor D.D., Palazzo J., Weese J.L. Intratumoral rIL-2-based immunotherapy in B16 melanoma. J. Surg. Res. 53:1992;203-210.
8. Tohmatsu A., Okino T., Stabach P., Padula S.J., Ergin M.T., Mukherij B. Analysis of cytolytic effector cell response in vitro against autologous human tumor cells genetically altered to synthesize interleukin-2. Immunol. Lett. 35:1993;51-57.
9. Karp S.E., Farber A., Salo J.C., Hwu P., Jaffe G., Asher A.L., Shiloni E., Restifo N.P., Mulé J.J., Rosenberg S.A. Cytokine secretion by genetically modified non-immunogenic murine fibrosarcoma. Tumor inhibition by but not tumor necrosis factor. J. Immunol. 150:1993;896-908.
10. Gansbacher B., Zier K., Daniels B., Cronin K., Bannerji R., Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172:1990;1217-1224.
11. Bannerji R., Arroyo C.D., Cordon-Cardo C., Gilboa E. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J. Immunol. 152:1994;2324-2332.
12. Conner J., Bannerji R., Saito S., Heston W., Fair W., Gilboa E. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J. Exp. Med. 177:1993;1127-1134.
13. Spaete R.R., Frenkel N. The herpes simplex virus amplicon: a new eukaryotic defective-virus cloning amplifying vector. Cell. 30:1982;295-304.
14. Kaplitt M.G., Pfaus J.G., Kleopoulos S.P., Hamlon B.A., Rabkin S.D., Pfaff D.W. Expression of functional foreign gene in adult mammalian brain following in vivo transfer via a herpes simplex virus type 1 defective viral vector. Mol. Cell. Neurosci. 2:1991;320-330.
15. Deluca N.A., MacCarthy A.M., Schaffer P.A. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP-4. J. Virol. 56:1985;558-578.
16. Vokes E.E., Weichselbaum R.R., Lippman S.M., Hong W.K. Head and neck cancer. N. Engl. J. Med. 328:1993;184-194.
17. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics. CA Cancer J. Clin. 47:1997;5-27.
18. Mosmann T.R., Coffman R.L. Two types of mouse helper-T-cell clone. Immunol. Today. 8:1987;223-227.
19. Rosenberg S.A., Lotze M.T. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Ann. Rev. Immunol. 4:1986;681-709.
20. Baccarini M., Schwinzer R., Lohmann-Matthes M.L. Effect of human recombinant IL-2 on murine macrophage precursors. Involvement of a receptor distinct from the p55 (Tac) protein. J. Immunol. 142:1989;118-125.
21. Rees R.C., Wiltrout R.H. The biology and clinical applications of interleukin 2. Immunol. Today. 11:1990;36-38.
22. Tung C., Federoff H.J., Brownlee M., Karpoff H., Weigel T., Brennan M.F., Fong Y. Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: implications for autologous vaccine production. Hum. Gene Ther. 7:1996;2217-2224.
23. Gansbacher B., Zier K., Cronin K., Hantzopoulos P.A., Bouchard B., Houghton A., Gilboa E., Golde D. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. Blood. 80:1992;2817-2825.
24. Patel P.M., Flemming C.L., Fisher C., Porter C.D., Thomas J.M., Gore M.E., Collins M.K. Generation of interleukin-2-secreting melanoma cell populations from resected metastatic tumors. Hum. Gene Ther. 5:1994;577-584.
25. Heike Y., Takahashi M., Kanegae Y., Sato Y., Saito I., Saijo N. Interleukin-2 gene transduction into freshly isolated lung adenocarcinoma cells with adenoviral vectors. Hum. Gene Ther. 8:1997;1-14.
26. Arienti F., Sulé-suso J., Melani C., Maccalli C., Belli F., Illeni M.T., Anichini A., Cascinelli N., Colombo M.P., Parmiani G. Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. Hum. Gene Ther. 5:1994;1139-1150.
27. Cignetti A., Guarini A., Carbone A., Forni M., Cronin K., Forni G., Gansbacher B., Foa R. Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression. J. Natl. Cancer Inst. 86:1994;785-791.
28. Chen L.K., Tourvieille B., Burns G.F., Bach F.H., Mathieu-Mahul D., Sasportes M., Bensussan A. Interferon: a cytotoxic T lymphocyte differentiation signal. Eur. J. Immunol. 16:1986;767-770.
29. Catalona W.J., Ratliff T.L., MacCool R.E. gamma-Interferon induced by S. aureus protein A augments natural killing and ADCC. Nature. 291:1981;77-79.
30. Adams D.O., Hamilton T.A. Molecular transduction mechanism by which IFN gamma and other signals regulate macrophage development. Immunol. Rev. 97:1987;5-27.
31. Tasaki K., Tagawa M., Gunji Y., Matsubara H., Takenaga K., Muramatsu M., Fujimura S., Suzuki T., Asano T., Ochiai T., Isono K., Kouzu T., Sakiyama S. Inhibition of experimental lung metastasis of murine colon carcinoma cells depend on the amount of interleukin-2 secreted from transduced cells. Anticancer Res. 18:1998;813-817.
32. Abdel-Wahab Z., Li W.P., Osanto S., Darrow T.L., Hessling J., Vervaert C.E., Burrascano M., Barber J., Seigler H.F. Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host antitumor immunity: a nude mouse model. Cell. Immunol. 159:1994;26-39.